UBRELVY

USDailyMed:Ubrogepant N02CD04(WHO) CA:℞-onlyUS:℞-only (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide 1374248-77-7 68748835 DB15328 28536135 AD0O8X2QJR D10673 ChEMBL2364638 DTXSID00160178 Interactive image C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1Key:DDOOFTLHJSMHLN-ZQHRPCGSSA-N Ubrogepant, sold under the brand nameUbrelvy, is amedicationused for the acute (immediate) treatment ofmigrainewith or withoutaura(a sensory phenomenon or visual disturbance) in adults.It is not indicated for the preventive treatment of migraine.Ubrogepant is a small-moleculecalcitonin gene-related peptide receptor antagonist.It is the first drug in this class approved for the acute treatment of migraine. The most common side effects arenausea,tirednessanddry mouth.Ubrogepant is contraindicated for co-administration with strongCYP3A4inhibitors.